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Abstract
Background: VEGF is a well-validated target for antiangiogenic intervention in cancer. To date, RNAi technology has 
been proven to be a promising approach for targeted therapy. DDP is frequently used as a first-line drug in 
chemotherapy for lung cancer but usually causes severe toxicity. In this study, we investigated a novel strategy of 
administering and combining RNAi mediated VEGF-targeted therapy with DDP for treatment of lung cancer, with the 
aim of increasing efficacy and decreasing toxicity.
Methods: In this study, a plasmid encoding VEGF shRNA was constructed to knockdown VEGF both in vitro and in vivo. 
In vitro, specificity and potency of the targeting sequence were validated in A549 lung adenocarcinoma cells by RT-
PCR and ELISA assays. In vivo, therapy experiments were conducted on nude mice bearing A549 xenograft tumors. The 
VEGF shRNA expressing plasmids were administered systemically in combination with low-dose DDP on a frequent 
basis. The tumor volume and weight were measured. MVD, the number of apoptotic cells and proliferation index in 
tumor tissues were assessed by CD31, TUNEL and PCNA immunostaining.
Results: The VEGF shRNA was highly effective in attenuating VEGF expression both in vitro and in vivo. The treatment 
with the VEGF shRNA alone reduced the mean tumor weight by 49.40% compared with the blank control (P < 0.05). 
The treatment with the VEGF shRNA plus DDP yielded maximal benefits by reducing the mean tumor weight by 
83.13% compared with the blank control (P < 0.01). The enhanced antitumor efficacy was associated with decreased 
angiogenesis and increased induction of apoptosis.
Conclusions: Our study demonstrated synergistic antitumor activity of combined VEGF shRNA expressing plasmids 
and low-dose DDP with no overt toxicity, suggesting potential applications of the combined approach in the 
treatment of lung cancer.
Background
Lung cancer is the leading cause of cancer-related death.
NSCLC accounts for 80%-85% of all lung cancers [1].
Approximately 75% of lung carcinoma patients are diag-
nosed with locally advanced or metastatic disease. Most
of those diagnosed with early-stage disease experience
relapse and the majority of them eventually die from met-
astatic disease [1,2]. Despite intensive efforts in treatment
practices, the survival rate for lung cancer has not
improved substantially in the past 25 years, resulting in a
5-year survival rate of approximately 15% [1]. Clinical
outcomes have reached a plateau in survival for which
new therapeutic strategies may exert benefits.
It is well known that the growth, persistence and metas-
tasis of solid tumors are angiogenesis-dependent, so anti-
angiogenic therapy offers hope for treatment of solid
tumors, including NSCLC [3]. Recent advances in the
knowledge of tumor angiogenesis have shed light on the
pivotal role of VEGF [4,5]. VEGF functions mostly as an
endothelial cell-specific mitogen which mediates numer-
ous changes within the tumor vasculature, including
endothelial cell survival, proliferation, migration, vascular
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Page 2 of 9permeability and vasodilation [4]. Recognition of the
VEGF pathway as a pivotal regulator of tumor angiogene-
sis has induced the development of various VEGF-tar-
geted agents. These agents include neutralizing
antibodies to VEGF or its receptors [6], tyrosine kinase
inhibitors (TKIs) for VEGFRs [7], soluble antagonists for
VEGF or VEGFRs [8] and so on. Some of them have been
tested in the clinic. However, a large proportion of exist-
ing VEGF-targeted agents were found to have modest
efficacy, when used singly in treatment of various cancers
except for certain specific types of malignancy. They have
thus mainly been used in combination with chemother-
apy or radiotherapy. An example of this is bevacizumab
(Avastin), a humanized monoclonal antibody to VEGF,
which is only of benefit for patients with NSCLC when
combined with conventional chemotherapy [9]. Investi-
gations are underway with the aim of exploring more
effective ways of administering and combining anti-
VEGF agents with chemotherapeutic drugs.
Chemotherapy has dominated systemic therapy of can-
cer for a long time. In the setting of metastatic disease,
chemotherapy used to be the only available approach. For
NSCLC, DDP-based regimen remains the mainstay of
chemotherapeutic treatment of patients with either
resected or locally advanced or, metastatic diseases
[2,10]. DDP-based regimens often cause severe toxic side
effects, including myelosuppression, asthenia and gastro-
intestinal disorder, as well as long-term cardiac, renal and
neurological consequences. These adverse events usually
cause drug discontinuation, poor tolerance and limited
therapeutic efficacy [11,12]. Preclinical and clinical stud-
ies are in progress to test various dosing/scheduling strat-
egies for chemotherapy to increase efficacy and decrease
toxicity.
Thus far, most existing VEGF-targeted agents belong to
the category of recombinant protein. However, RNAi
technology has been proven to be a promising alternative
approach for targeted therapy and various RNAi tools are
under intensive investigation. In this study, we investi-
gated a novel strategy of administering and combining
RNAi mediated VEGF-targeted therapy with DDP for
treatment of lung cancer.
Methods
Construction of shRNA expressing plasmid
A plasmid-based shRNA expression system was used to
endogenously express shRNA in human cancer cells. The
targeted sequence of human VEGF: 5'-AAA CCU CAC
CAA GGC CAG CAC-3' (21 nt) was selected according
to a previous study [13]. The control sequence which was
named HK: 5'-GAC TTC ATA AGG CGC ATG C-3' (19
nt) had no homology to any mammalian sequence.
Recent evidence has revealed that U6 promoter is greatly
superior to the other promoters in driving plasmid based
shRNA expression and pU6shRNA is at least 100-fold
more potent in gene silencing than corresponding siRNA
on a numerical basis [14]. Thus, we elected U6 promoter
to control the recombinant plasmids which were con-
structed and prepared as described elsewhere [15]. The
resulting plasmids were named pshVEGF and pshHK,
respectively. Oligonucleotide sequences of pshVEGF
were: sense 5'-GAT CCA CCT CAC CAA GGC CAG
CAC TTC AAG ACG GTG CTG GCC TTG GTG AGG
TTT TTT TGA GCT CA-3'; antisense 5'-AGC TTG
AGC TCA AAA AAA CCT CAC CAA GGC CAG CAC
CGT CTT GAA GTG CTG GCC TTG GTG AGG TG-3'.
Cell lines and transfection conditions
The A549 cell line was purchased from the American
Type Culture Collection (ATCC, Manassas, VA, USA).
The cells were cultured in RPMI1640 medium (Life Tech-
nologies, Bedford, MA, USA) supplemented with 10%
fetal bovine serum and 100 U/ml penicillin and 100 U/ml
streptomycin. All the Cells were maintained in a humidi-
fied atmosphere of 5% CO2 at 37°C.
Cell transfection was performed using FugeneHD
(Roche, Mannheim, Germany) according to the manufac-
turer's recommendation. Briefly, A549 cells were seeded
in 6-well plates at a density of 3 × 105 cells/well and cul-
tured to reach 70-80% confluence. Two μg plasmid DNA
(pshVEGF or pshHK) and 5 μl FugeneHD diluted in
serum-free medium were mixed and the complex was
added to the cell cultures. Growth medium was used as
the control agent. The cells and the supernatants were
harvested 48 h after transfection for semiquantitative RT-
PCR and ELISA assays. All the transfections were per-
formed in triplicate.
Semiquantitative RT-PCR and ELISA assays
Total RNA was extracted from the cells with Trizol
Reagent (Invitrogen, Grand Island, NY, USA). RNA con-
centration was measured by spectrophotometry. RT-PCR
was performed with the isolated total RNA (1 μg) using
TaKaRa Onestep RNA PCR Kit (Takara, Japan). β-actin
was amplified as the internal control. The primers for
VEGF were: forward, 5'-ATC ACG AAG TGG TGA AGT
TC-3'; reverse, 5'-TGC TGT AGG AAG CTC ATC TC-3'.
The expected sizes of PCR products are 265 bp for VEGF
and 512 bp for β-actin [16]. VEGF and β-actin cDNA
were amplified by 30 cycles of denaturation for 2 min at
94°C, annealing for 0.5 min at 62°C and extension for 0.5
min at 72°C. After the amplification, each product (10 μl)
was loaded on 1% agarose gel for electrophoresis. The
amplified products were quantified by Quantity One
(Bio-Rad, Richmond, CA, USA). Each experiment was
performed in triplicate.
Secretion of VEGF into the cell culture supernatant and
tumor contents of VEGF in the A549 xenografts were
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tech, Wuhan, China) according to the manufacturer's
instructions. The results of the ELISA assay in the cell
culture supernatants were expressed as pg/ml/105 cells.
VEGF concentration in the tumors was corrected for
total protein. Each experiment was performed in tripli-
cate.
Preparation of lipoplexes for in vivo therapy
The cationic liposome DOTAP and cholesterol were pur-
chased from Avanti Polar Lipids (Alabaster, AL, USA)
and Sigma (St. Louis, MO, USA), respectively.
DOTAP:Chol was prepared as described elsewhere [17].
Before tail vein injection, lipoplexes were prepared as fol-
lows: 5 μg DNA and 25 μg DOTAP:Chol were diluted
respectively in 50 μl 5% GS. The DNA solution was added
into the liposome solution dropwisely. The mixture was
incubated at room temperature for 30 min prior to injec-
tion.
Freshly prepared lipoplexes were analyzed for particle
size by Malvern Zen 600 Zetasizer (Malvern, Spectris,
Worcestershire, UK). The particle sizes of the lipoplexes
generally ranged between 200 nm and 300 nm.
In vivo tumor models and systemic treatment
The following studies were approved by the Institutional
Animal Care and Treatment Committee of Sichuan Uni-
versity (Chengdu, China). To rule out the contribution of
host immune response, we used a nude mouse model.
Female athymic nude mice (BALB/c, 4-6 weeks of age)
were housed in standard microisolator conditions free of
pathogens in accordance with institutional guidelines
under approved protocols. In all the experiments, 5 × 106
A549 cells suspended in 100 μl sterile PBS were injected
in right flanks of the mice. When the tumors reached a
mean diameter of 4-5 mm one week later, the animals
were randomly assigned into groups and the treatment
was initiated. There were five groups. Each group con-
sisted of five animals. Group 1 received 5% GS. Group 2
received pshHK lipoplex. Group 3 received pshVEGF lip-
oplex. Group 4 received DDP. Group 5 received the com-
bination of the regimens of group 3 and 4. The lipoplexes
were administered intravenously three times per week for
four weeks. DDP (2 mg/kg) was administered intraperito-
neally twice per week for two weeks, starting on the next
day after the administration of pshVEGF lipoplex. Our
laboratory has tested various dosages of DDP and dem-
onstrated that the dose 5 mg/kg/week is safe and effective
for mice in our laboratory. To mimic 'metronomic' che-
motherapy, that is, relatively frequent administrations of
relatively low doses of chemotherapy, we administered
DDP at 2 mg/kg twice a week. During the course of treat-
ment, tumor size was measured by a caliper and tumor
volume was calculated using the formula: V(volume) =
LW2 × π/6 where " L " represents the greatest length and "
W " represents the perpendicular width[18]. The animals
were sacrificed after twelve times of treatment. The
tumors were excised and weighed. The tumor specimens
were fixed in 4% formaldehyde, embedded in paraffin,
and cut in 4 μm sections for immunohistochemical analy-
sis.
Immunohistochemistry
Immunohistochemical analysis of VEGF, CD31 and
PCNA expression were performed according to the pro-
cedure described elsewhere [15]. The primary antibodies
were mouse anti-human VEGF antibody, goat anti-mouse
CD31 antibody and mouse anti-human PCNA antibody (
Santa Cruz Biotechnology, Santa Cruz, CA, USA).
To quantify MVD, each slide was scanned at low power
magnification (× 10-100). Two 'hot spot' areas with rela-
tively higher number of new vessels were identified which
were subsequently scanned at high power magnification
(× 400). Five random fields of each 'hot pot' area were
analyzed. To determine proliferation index, the number
of PCNA-positive cells was counted in 10 random fields
(× 400).
In situ TUNEL assay for apoptotic cells
DNA fragmentation morphology of the tumor tissues
was evaluated using DeadEnd™ Fluorometric TUNEL
System (Promega, Madison, Wisc., USA) according to the
manufacturer's protocol. The number of green fluores-
cence-positive cells was counted in 10 random fields (×
400).
Toxicity assessment
The treatment-related toxicity was mainly evaluated by
weight changes of the mice. During the whole treatment
course, other toxicity indexes such as ruffling of fur,
behavior, feeding, cachexia and toxic death were moni-
tored. The tissues of organs (hearts, livers, spleens, lungs
and kidneys) were fixed and embedded in paraffin. The
sections of 4 μm were stained with H&E and observed by
two pathologists in a blinded manner.
Statistical analysis
Data were expressed as the mean ± SD. For comparison
of individual time points, differences between groups
were tested by performing one-way analysis of variance
(ANOVA). All P values were two sides and P < 0.05 was
considered statistically significant. The Statistical Pack-
age for the Social Sciences (SPSS version 16.0, Inc., Chi-
cago, IL. USA) was used for all statistical analysis.
Results
In vitro downregulation of VEGF by pshVEGF
To evaluate specificity and potency of the targeting
sequence in A549 cells, we examined its effects on VEGF
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measure changes in VEGF expression at the mRNA level.
Cells were transiently transfected with pshVEGF and
pshHK, harvested 48 h later and subjected to RT-PCR
analysis. As shown in Fig. 1A.B, attenuation of VEGF
expression was distinct 48 h after transfection with psh-
VEGF, whereas VEGF expression was not affected by
pshHK. As VEGF mainly exerts its functions after it is
secreted by tumor cells into the microenvironment, we
then performed ELISA assay to measure the secreted
VEGF protein levels in the supernatants. At 48 h post-
transfection, the supernatants were collected. Cell viabil-
ity, as assessed by trypan blue staining, was good (about
90%) and comparable for all experimental groups. The
cells treated with liposome alone in exhibited almost the
same viability as the cells in the other groups, indicating
that the liposome we used has no apparent toxicity. As
shown in Fig. 1C, VEGF expression in the supernatants
derived from pshVEGF transfected cells was sharply
decreased, whereas significantly higher levels of VEGF in
the supernatants of pshHK or mock transfected cells
were detected (about 370 pg/ml/105 cells). The VEGF
shRNA eventually lowered the secreted amount of VEGF
by 70.32% when compared with the HK shRNA (P <
0.05), which was highly consistent with the results of RT-
PCR analysis. Thus, we demonstrated that the VEGF
shRNA was able to knockdown VEGF expression in A549
cells with high specificity and potency.
In vivo therapy with the combination treatment
Having confirmed the specificity and potency of the
VEGF shRNA, we then combined it with DDP in an ani-
mal model to investigate the antitumor efficacy of the
combination treatment. We used a nude mice model to
rule out the contribution of the host immune system.
Mice bearing A549 derived tumors were treated as
described in the "Methods" section. As shown in Fig.
2A.B, either pshVEGF or DDP individually effectively
slowed down the tumor growth rate, reducing the tumor
weight by 49.40% and 50.20% compared with 5% GS (P <
0.05). The combination treatment had a significantly
enhanced antitumor effect compared with the treatment
with pshVEGF or DDP alone (P < 0.05), resulting in
reduction in the tumor weight by 83.13% compared with
the treatment with 5% GS (P < 0.01). We didn't monitor
survival because the knockdown effects may fade over
time and become too modest to be examined. To prove
that the therapeutic effects were related to downregula-
tion of VEGF expression instead of other nonspecific
reactions, we harvested the tumors for immunohis-
tochemistry and ELISA assay to measure VEGF expres-
sion. As shown in Fig. 3A, we analyzed the gross
distribution of immunoreactive VEGF in the tumors and
observed a general decrease of VEGF staining in the
tumors belonging to the mice treated with pshVEGF,
whereas the tumors belonging to the mice treated with
pshHK exhibited significantly more VEGF staining. Con-
sistently, the ELISA assay showed that pshVEGF caused
significant reduction in intratumoral VEGF expression
compared with pshHK, as shown in Fig. 3B. Thus, we
Figure 1 Attenuation of VEGF expression in vitro. A) Photograph of 
agarose gel. Cultured A549 cells were transfected with pshVEGF or 
pshHK. Forty-eight hours after transfection, VEGF mRNA was semi-
quantified by RT-PCR. The β-actin gene was used as the internal con-
trol. B) Densitometric analysis of VEGF mRNA was done and the relative 
expression of each band was normalized to the blank control (5% GS). 
C) Forty-eight hours after transfection, supernatants were collected 
and assayed for secreted VEGF protein by ELISA. The results are pre-
sented as mean ± SD (n = 3). P < 0.05 versus pshHK.
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geting sequences.
Effect of the combination treatment on angiogenesis, cell 
apoptosis, and proliferation
To determine the mechanisms of the enhanced efficacy of
the combination treatment, we examined its effects on
tumor angiogenesis (MVD), tumor cell apoptosis
(TUNEL) and proliferation (PCNA). We first evaluated
vessel density in the harvested tumors. As shown in Fig.
4A, the mean MVD was reduced apparently in the
tumors belonging to the mice treated with pshVEGF or
DDP alone compared with 5% GS or pshHK. The most
significant reduction in MVD occurred in the tumors of
the mice receiving the combination treatment compared
with pshVEGF or DDP alone (P < 0.05). Then we evalu-
ated tumor cell apoptosis using in situ TUNEL assay. As
shown in Fig. 4B, apparent cell apoptosis was identified in
the tumors belonging to the mice treated with pshVEGF
or DDP alone when compared with 5% GS or pshHK. The
most significant apoptosis was observed in the tumors of
the mice receiving the combination treatment compared
with pshVEGF or DDP alone (P < 0.05). Finally, we evalu-
ated tumor cell proliferation using PCNA staining. As
shown in Fig. 4C, an apparent reduction of PCNA expres-
sion was observed in the tumors belonging to the mice
treated with DDP alone compared with 5% GS or pshHK,
whereas no overt reduction was observed in the tumors
of the mice treated with pshVEGF alone. However, the
most significant reduction of PCNA expression was
observed in the tumors of the mice receiving the combi-
nation treatment compared with pshVEGF or DDP alone
(P < 0.05). No significant difference in tumor angiogene-
sis, tumor cell apoptosis or proliferation was found
between the pshHK group and the 5% GS group.
Toxicity observation
To evaluate treatment-related toxicity, we used body
weight as a surrogate for the general health status of the
mice. Weight of the mice was measured regularly. The
mice treated with pshVEGF, DDP and the combination of
both showed a slight delay in weight gain. The mice
receiving DDP or the combination treatment exhibited
temporal weight loss. On the whole, there was no signifi-
cant difference in body weight among the five groups. No
adverse consequences in other gross measures, such as
ruffled fur, strange behaviors, or toxic deaths were found
in any group. Furthermore, no pathologic changes were
observed in the organs (heart, liver, spleen, lung and kid-
ney) of the mice macroscopically. Microscopic examina-
tion revealed no vascular endothelial damage,
hemorrhage or edema in any organ.
Discussion
The majority of NSCLC patients are diagnosed with late-
stage disease and have poor prognosis. Clinical outcomes
have reached a plateau with conventional chemotherapy
as the main treatment of choice. In such clinical setting,
an aggressive regimen of chemotherapy may not only fail
in benefiting in survival but also harm the quality of life.
To address the issue, targeted therapy was introduced.
Based on advances in the knowledge of molecular events
involved in NSCLC, a number of agents have been devel-
oped to specifically target signaling pathways critical to
tumor progression. These rationally designed drugs were
originally developed to replace conventional chemother-
apy. However, numerous clinical trials have revealed the
fact that a few of them managed to increase survival sig-
nificantly only in combination with standard chemother-
Figure 2 Antitumor effect of VEGF silencing plus DDP on A549 
cells in vivo. Tumor growth curves. Each point in the curves represents 
the mean ± SD (n = 5 tumors). The therapy started on day 7 when the 
tumors reached a volume of ~50 mm3. The combination of VEGF si-
lencing plus DDP enhanced the inhibition of tumor growth, #P < 0.05 
versus 5% GS, *P0.05 versus pshVEGF or DDP, **P < 0.01 versus 5% GS. 
B) Weight of the tumors. Each bar represents the mean ± SD (n = 5 tu-
mors). *P < 0.05 versus pshVEGF or DDP. Mean weights of the tumors 
are 0.510 g, 0.490 g, 0.242 g, 0.228 g and 0.110 g, for the 5% GS group, 
the pshHK group, the pshVEGF group, the DDP group and the psh-
VEGF plus DDP group, respectively.
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Page 6 of 9apy [19]. It appears that sole targeted therapy is not
sufficient to gain benefits to the extent desired. One
explanation is that when certain pathways are blocked,
other pathways may compensate the loss. Another expla-
nation is that subgroups of patients who will hopefully
gain maximal benefits from targeted therapy have been
far from clearly identified, therefore modest efficacy was
shown in general population. A third explanation is that
recombinant protein antagonists, the use of which domi-
nates current targeted therapy, have intrinsic disadvan-
tages that limit therapeutic efficacy [20]. At the present
stage, it makes sense to design effective alternative com-
binatorial therapies that combine agents with novel, mul-
tiple, functionally linked properties.
The present study is a new attempt to explore a poten-
tially effective way of administering and combining
VEGF-targeted agents to first-line chemotherapeutic
drugs in the treatment of NSCLC. The key findings of
this study are that the combination strategy of the VEGF-
targeted shRNA and low-dose DDP showed synergistic
antitumor efficacy that could not be achieved with either
alone, including tumor growth inhibition, neovascular-
ization suppression and tumor apoptosis augmentation.
None of serious adverse consequences, such as weight
loss, strange behaviors, cachexia or toxic death, were
observed.
Mechanisms of the enhanced antitumor efficacy
remain to be fully elucidated, however, two mechanisms
may get involved. The enhanced antitumor efficacy in
vivo may be attributed to decreased angiogenesis and
increased induction of apoptosis. This speculation is sup-
ported by our findings. Apparently less microvessel count
and more apoptotic cells were found in the tumors
belonging to the mice treated with pshVEGF plus DDP
than with either alone. The first mechanism is decreased
angiogenesis by the combination treatment. VEGF has
been shown to function primarily via VEGFR2 which is
selectively expressed on tumor endothelial cells. Several
lines of evidence have revealed that binding of VEGF to
VEGFR2 activates the phosphatidylinositol 3-kinase
(PI3K)/AKT signaling pathway which upregulates several
downstream pro-survival molecules, such as survivin,
XIAP and bcl-2 [21-23]. These effectors act to shield
tumor endothelial cells from various stress situations. It is
known that besides tumor cells, active tumor endothelial
cells are also targets of cytotoxic chemotherapeutics that
were designed to kill rapidly dividing cells. Thus, depriva-
tion of VEGF in the tumor microenvironment blocks
VEGF-dependent pro-survival pathways in tumor
Figure 3 Knockdown of VEGF expression in vivo. A) Representative photographs of the tumor sections examined by immunohistochemical stain-
ing for VEGF (×400 magnification). The assessment of VEGF was based on a cytoplasmic staining pattern. B) The tumors were harvested and assayed 
for VEGF protein by ELISA. The results are presented as mean ± SD (n = 3 tumors). *P < 0.05 versus pshHK.
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chemotherapeutic attacks. DDP has been found to exert
its cytotoxicity to various cancer cell lines through induc-
tion of apoptosis by damaging DNA [24,25]. There is also
evidence that DDP inhibits endothelial cell proliferation
through suppressing DNA synthesis [26]. It appears that
the proapoptotic and antiproliferating effects of DDP to
endothelial cells are amplified along with the knockdown
of VEGF. The knockdown of VEGF and cytotoxicity of
DDP are in synergy with each other in terms of inhibiting
neovascularization. The second mechanism is increased
induction of apoptosis. As a result of reduced vascular
density and perfusion due to inhibited angiogenesis,
tumor cells are deprived of sufficient nourishments dur-
ing their regrowth after chemotherapeutic insults. Mean-
while, impaired endothelium increases vascular
permeability which leads to more exposure of tumor cells
to chemotherapeutic drugs. The proapoptotic effects of
DDP are therefore strengthened. As it is unclear whether
direct effects of VEGF RNAi on the tumor cells syner-
gized with DDP to induce apoptosis, we performed flow
cytometry analysis, caspase-3 assay to detect apoptosis
and MTT assay to measure cytotoxicity with the cultured
cells transfected with the different plasmids (pshVEGF or
Figure 4 Inhibition of tumor angiogenesis, apoptosis and proliferation by VEGF silencing plus DDP in vivo. A) Representative photographs of 
the tumor sections examined by immunohistochemical staining for CD31 showing tumor vasculature (×400 magnification). Each bar represents the 
average vessel number for each group, expressed as mean ± SD. *P < 0.05 versus pshVEGF or DDP. B) Representative photographs of the tumor sec-
tions examined by TUNEL assay. TUNEL-positive cell nuclei (green) were observed under a fluorescence microscope (×400). Each bar represents the 
'apoptosis index', expressed as mean ± SD.*P < 0.05 versus pshVEGF or DDP. C) Representative photographs of the tumor sections examined by im-
munohistochemical staining for PCNA (×400). The assessment of PCNA was based on a nuclear staining pattern. Each bar represents the ratio of PCNA 
positive cells to the total number of cells for each group, expressed as mean ± SD. *P < 0.05 versus pshVEGF or DDP.
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revealed that a) transfection with pshVEGF didn't
increase cell apoptosis when compared with pshHK; b)
VEGF RNAi didn't sensitize the cells to DDP in terms of
inducing cell apoptosis; c) VEGF RNAi didn't signifi-
cantly lower IC50 of DDP to A549 cells. These findings
rule out direct synergistic effects of VEGF RNAi plus
DDP on the tumor cells.
It is worth mentioning that the success in the present
study is based on the dosing/scheduling strategy that was
adopted for the therapy. Thus far, there are few reports
describing the duration of RNAi effect on endogenous
target genes [27]. On the basis of the in vitro result that
attenuation of VEGF expression was distinct 48 h after
plasmid transfection, the plasmids were given to the mice
every other day at a dose of 5 μg. It was supposed that
specific knockdown effects could be maintained and
strengthened in this way without severe toxicities that
have been reported to come with the use of short bursts
of high-dose DNA/liposome complex [28]. Based on the
same consideration about toxicity, DDP was administered
in a similar way. It was given to the mice at the dose of 2
mg/kg twice a week instead of at maximum tolerated
dose(9 mg/kg/week)[29]. In this study, the enhanced effi-
cacy without overt toxicity suggested the effectiveness of
the dosing/scheduling strategy.
The success of gene therapy is highly dependent on
delivery vector. In this study, we elected the cationic lipo-
some DOTAP:Chol as the delivery vector. It is a well-
characterized nonviral vector and has been advanced into
phase I clinical trial for treatment of NSCLC [30-32]. In
this study, attenuation of VEGF expression in vivo con-
firmed the successful delivery of DOTAP:Chol.
Conclusions
In summary, our study shows that the combination of
plasmid-encoding VEGF shRNA and low-dose DDP is
highly effective in inhibiting NSCLC growth in vivo with-
out overt toxicity. The enhanced antitumor efficacy may
be attributed to synergistic mechanisms of decreased
angiogenesis and increased induction of apoptosis. Our
findings suggest the potential use of the combined
approach in treatment of lung cancer.
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